InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Ionomycin | Invasive Rhinosinusitis Caused by Alternaria infectoria in a Patient with Aut... | 2022 | J Fungi (Basel) | Paccoud O. et al. | DOI: 10.3390/jof8050446 |
| HKCA | Invasive Rhinosinusitis Caused by Alternaria infectoria in a Patient with Aut... | 2022 | J Fungi (Basel) | Paccoud O. et al. | DOI: 10.3390/jof8050446 |
| NLRP3 KO & KD THP-1 Cells | Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to A... | 2022 | Pharmaceuticals (Basel) | Tengesdal I.W. et al. | DOI: 10.3390/ph15050574 |
| THP1-Null Cells | Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to A... | 2022 | Pharmaceuticals (Basel) | Tengesdal I.W. et al. | DOI: 10.3390/ph15050574 |
| TLR 5 | Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion ... | 2022 | Pharmaceutics | Chen C.H. et al. | DOI: 10.3390/pharmaceutics14051014 |
| Recombinant anti-PD-L1 antibodies (D265A) - InvivoFit™ | Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to... | 2022 | Nat Cancer | Falcomatà C. et al. | DOI: 10.1038/s43018-021-00326-1 |
| IL-12 Reporter HEK 293 Cells | Intratumoral immunotherapy relies on B and T cell collaboration. | 2022 | Sci Immunol. | Sagiv-Barfi I. et al. | DOI: 10.1126/sciimmunol.abn5859 |
| IL-12 Reporter HEK 293 Cells | Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of pla... | 2022 | Mol Ther Oncolytics | Lee J.Y. et al. | DOI: 10.1016/j.omto.2022.04.005 |
| Recombinant anti-mouse PD-1 antibody - Clone RMP1-14 (D265A) | Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of pla... | 2022 | Mol Ther Oncolytics | Lee J.Y. et al. | DOI: 10.1016/j.omto.2022.04.005 |
| QUANTI-Blue™ | Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of pla... | 2022 | Mol Ther Oncolytics | Lee J.Y. et al. | DOI: 10.1016/j.omto.2022.04.005 |
| IL-12 Reporter HEK 293 Cells | A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control... | 2022 | Sci Immunol. | Xue D. et al. | DOI: 10.1126/sciimmunol.abi6899 |
| HEK-Blue™ Selection | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
| IL-12 Reporter HEK 293 Cells | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
| IL-18 Reporter HEK 293 Cells | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
| QUANTI-Blue™ | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
| Recombinant human IL-18 | A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-... | 2022 | Mol Ther Oncolytics | Cubitt C.C. et al. | DOI: 10.1016/j.omto.2022.02.009 |
| Poly(I:C) (HMW) VacciGrade™ | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
| CL075 (3M002) | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
| ssRNA40/LyoVec™ | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |
| 2’3’-cGAM(PS)2 (Rp/Sp) | Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-der... | 2022 | J Immunother Cancer | He M. et al. | DOI: 10.1136/jitc-2021-004268 |